Kenvue Inc.
Kenvue Announces Executive Transition in Asia Pacific Region
Summary
On June 24, 2025, Kenvue Inc. announced the departure of Ellie Bing Xie, Group President, Asia Pacific, effective July 14, 2025. Xie will be succeeded by Anindya (Andy) Dasgupta, a seasoned executive with nearly 30 years of global consumer products industry experience. The transition is part of a planned succession and does not involve any findings of cause under the company's Executive Severance Pay Plan. Xie will remain with the company until August 8, 2025, to assist with the transition. Dasgupta will lead the Asia Pacific region, which contributed approximately $3 billion in net sales in fiscal year 2024.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement